Try a new search

Format these results:

Searched for:

person:millea51

in-biosketch:true

Total Results:

44


In-depth characterization of vaccine-induced neoantigen-specific T cells in patients with IDH1-mutant glioma undergoing personalized peptide vaccination

Zelba, Henning; Shao, Borong; Rabsteyn, Armin; Reinhardt, Annekathrin; Greve, Carsten; Oenning, Lisa; Kayser, Simone; Kyzirakos, Christina; Latzer, Pauline; Riedlinger, Tabea; Bartsch, Oliver; Wünsche, Julian; Harter, Johannes; Feldhahn, Magdalena; Bantel, Yannick; Johänning, Janina; Ködding, Jiri; Hadaschik, Dirk; Schulze, Martin; Battke, Florian; Maksimovic, Olga; Scheble, Veit; Miller, Alexandra M; Castro, Michael; Blumenthal, Deborah T; Glas, Martin; Reardon, David; Biskup, Saskia
Isocitrate dehydrogenase (IDH) mutant glioma is a malignant primary brain tumor diagnosed in adults. In recent years, there has been significant progress in understanding the molecular pathogenesis and biology of these tumors. The first targeted IDH-inhibitor was approved by the US Food and Drug Administration in August 2024 for grade 2 gliomas, in light of results of a phase III trial which showed significant advantages in progression-free survival. However, biologic therapy is not curative, and subsequent treatment options offer only limited clinical benefit and often result in long-term toxicities. In addition, targeted treatment options for grade 3 and grade 4 IDH-mutant gliomas are still missing. In this study, we present n=52 patients with glioma (grade 2, 3 and 4) with confirmed IDH1 mutation (mutIDH1) in the newly diagnosed and recurrent setting who, in addition to standard-of-care, received a personalized neoantigen-targeting peptide vaccine. Each tumor was initially analyzed for somatic mutations by whole exome sequencing, and a peptide vaccine containing potential neoepitopes was designed, manufactured and vaccinated. Each vaccine consisted of peptides derived from numerous somatic mutations, including at least one peptide targeting the mutIDH1.Vaccine immunogenicity was determined by intracellular cytokine staining and simultaneous measurement of four T-cell activation markers (Interferon-γ, Tumor Necrosis Factor, Interleukin-2, CD154) after 12-day in vitro expansion of pre and post vaccination peripheral blood mononuclear cells. Extracellular CD154 staining was used to sort mutIDH1-specific CD4+T cells.Immunomonitoring revealed that the vaccines were immunogenic and induced mainly CD4 but also CD8 T cell responses. Vaccine-induced immune responses were robust and polyfunctional. Immunogenicity against mutIDH1 was high (89%). We implemented an assay which allowed us to isolate functional antigen-specific CD4+T cells in an HLA-independent manner. Subsequent T cell receptor (TCR) repertoire sequencing revealed that CD4+T cells reacting on mutIDH1 stimulation were polyclonal. Strikingly, we detected two mutIDH1-specific TCRβ candidate sequences in three different patients. These three patients had the same human leukocyte antigen (HLA) DQA-DQB alleles. The obtained TCRβ sequences could be tracked in autologous ex-vivo single-cell transcriptomic data. Our results provide a rationale for pursuing vaccination and T cell transfer strategies targeting IDH1. Furthermore, our findings indicate that personalized neoantigen-targeting vaccines might be considered for the treatment of IDH1-mutant gliomas.
PMID: 40480654
ISSN: 2051-1426
CID: 5862922

Improving global access to genomic profiling in rare pediatric cancers

Farouk Sait, Sameer; O'Donohue, Tara J; Bale, Tejus; Bowman, Anita; Hill, Katherine; Stockfisch, Emily; Giantini-Larsen, Alexandra; Alano, Tina; Rosenblum, Marc; Benhamida, Jamal; Dunkel, Ira J; Berger, Michael; Arcila, Maria E; Ladanyi, Marc; Ortiz, Michael V; Glade Bender, Julia; Miller, Alexandra; Chakravarty, Debyani; Cavender, Kelly; Preiser, Benjamin; Zhang, Hongxin; Kung, Andrew L; Solit, David B; Karajannis, Matthias A; Shukla, Neerav N
BACKGROUND:To address financial barriers that limit access to genomic profiling and precision medicine, philanthropy supported clinical genomic testing was offered worldwide at no cost to patients with select rare cancers via the Make-an-IMPACT program. Herein, we report our findings in pediatric patients with solid or central nervous system (CNS) tumors. METHODS:Tumor DNA or CSF-derived circulating tumor DNA (CSF ctDNA) was analyzed using the MSK-IMPACT assay, supplemented by targeted RNA panel sequencing in select cases. Results were returned to the patients/families and treating oncologists. RESULTS:63 patients from 11 countries had successful MSK-IMPACT testing. The results provided clinically relevant new diagnostic or prognostic information in 41% and 38% of solid and CNS tumor patients, respectively. Potentially therapeutically actionable alterations were identified in 44% of pediatric solid tumor and 21% of pediatric CSF ctDNA samples, respectively. Four patients subsequently received molecularly guided therapy, resulting in partial responses in two and prolonged stable disease in one. Serial tumor and CSF sampling identified resistance mutations in two patients, informing additional molecular targeted therapy recommendations. CONCLUSIONS:The Make-an-IMPACT program provided global access to state-of-the-art tumor and CSF genomic profiling across a diverse cohort of pediatric cancer patients, providing clinically relevant and actionable diagnostic, prognostic and therapeutic information reported in real time to patients and local physicians.
PMID: 40392980
ISSN: 1557-3265
CID: 5853032

A population-based analysis of the molecular landscape of glioma in adolescents and young adults reveals insights into gliomagenesis

Bennett, Julie; Levine, Adrian B; Nobre, Liana; Negm, Logine; Chung, Jiil; Fang, Karen; Johnson, Monique; Komosa, Martin; Krumholtz, Stacey; Nunes, Nuno Miguel; Rana, Mansuba; Ryall, Scott; Sheth, Javal; Siddaway, Robert; Bale, Tejus A; Bouffet, Eric; Cusimano, Michael D; Das, Sunit; Detsky, Jay; Dirks, Peter; Karajannis, Matthias A; Kongkham, Paul; Giantini-Larsen, Alexandra; Li, Bryan Kincheon; Lim-Fat, Mary Jane; Lin, Andrew L; Mason, Warren P; Miller, Alexandra; Perry, James R; Sahgal, Arjun; Sait, Sameer Farouk; Tsang, Derek S; Zadeh, Gelareh; Laperriere, Normand; Nguyen, Lananh; Gao, Andrew; Keith, Julia; Munoz, David G; Tabori, Uri; Hawkins, Cynthia
Gliomas are a major cause of cancer-related deaths in adolescents and young adults (AYAs; ages 15-39 years). Different molecular alterations drive gliomas in children and adults, leading to distinct biology and clinical consequences, but the implications of pediatric- versus adult-type alterations in AYAs are unknown. Our population-based analysis of 1,456 clinically and molecularly characterized gliomas in patients aged 0-39 years addresses this gap. Pediatric-type alterations were found in 31% of AYA gliomas and conferred superior outcomes compared to adult-type alterations. AYA low-grade gliomas with specific RAS-MAPK alterations exhibited senescence, tended to arise in different locations and were associated with superior outcomes compared to gliomas in children, suggesting different cellular origins. Hemispheric IDH-mutant, BRAF p.V600E and FGFR-altered gliomas were associated with the risk of malignant transformation, having worse outcomes with increased age. These insights into gliomagenesis may provide a rationale for earlier intervention for certain tumors to disrupt the typical behavior, leading to improved outcomes.
PMID: 40335748
ISSN: 2662-1347
CID: 5842472

Ultra-rapid droplet digital PCR enables intraoperative tumor quantification

Murphy, Zachary R; Bianchini, Emilia C; Smith, Andrew; Körner, Lisa I; Russell, Teresa; Reinecke, David; Maarouf, Nader; Wang, Yuxiu; Golfinos, John G; Miller, Alexandra M; Snuderl, Matija; Orringer, Daniel A; Evrony, Gilad D
BACKGROUND:The diagnosis and treatment of tumors often depend on molecular-genetic data. However, rapid and iterative access to molecular data is not currently feasible during surgery, complicating intraoperative diagnosis and precluding measurement of tumor cell burdens at surgical margins to guide resections. METHODS:Here, we introduce Ultra-Rapid droplet digital PCR (UR-ddPCR), a technology that achieves the fastest measurement, to date, of mutation burdens in tissue samples, from tissue to result in 15 min. Our workflow substantially reduces the time from tissue biopsy to molecular diagnosis and provides a highly accurate means of quantifying residual tumor infiltration at surgical margins. FINDINGS/RESULTS: = 0.995). CONCLUSIONS:The technology and workflow developed here enable intraoperative molecular-genetic assays with unprecedented speed and sensitivity. We anticipate that our method will facilitate novel point-of-care diagnostics and molecularly guided surgeries that improve clinical outcomes. FUNDING/BACKGROUND:This study was funded by the National Institutes of Health and NYU Grossman School of Medicine institutional funds. Reagents and instruments were provided in kind by Bio-Rad.
PMID: 40010345
ISSN: 2666-6340
CID: 5801032

Real-world experience with circulating tumor DNA in cerebrospinal fluid from patients with central nervous system tumors

Hickman, Richard A; Miller, Alexandra M; Holle, Bridget M; Jee, Justin; Liu, Si-Yang; Ross, Dara; Yu, Helena; Riely, Gregory J; Ombres, Christina; Gewirtz, Alexandra N; Reiner, Anne S; Nandakumar, Subhiksha; Price, Adam; Kaley, Thomas J; Graham, Maya S; Vanderbilt, Chad; Rana, Satshil; Hill, Katherine; Chabot, Kiana; Campos, Carl; Nafa, Khedoudja; Shukla, Neerav; Karajannis, Matthias; Li, Bob; Berger, Michael; Ladanyi, Marc; Pentsova, Elena; Boire, Adrienne; Brannon, A Rose; Bale, Tejus; Mellinghoff, Ingo K; Arcila, Maria E
The characterization of genetic alterations in tumor samples has become standard practice for many human cancers to achieve more precise disease classification and guide the selection of targeted therapies. Cerebrospinal fluid (CSF) can serve as a source of tumor DNA in patients with central nervous system (CNS) cancer. We performed comprehensive profiling of CSF circulating tumor DNA (ctDNA) in 711 patients using an FDA-authorized platform (MSK-IMPACT™) in a hospital laboratory. We identified genetic alterations in 489/922 (53.0%) CSF samples with clinically documented CNS tumors. None of 85 CSF samples from patients without CNS tumors had detectable ctDNA. The distribution of clinically actionable somatic alterations was consistent with tumor-type specific alterations across the AACR GENIE cohort. Repeated CSF ctDNA examinations from the same patients identified clonal evolution and emergence of resistance mechanisms. ctDNA detection was associated with shortened overall survival following CSF collection. Next-generation sequencing of CSF, collected through a minimally invasive lumbar puncture in a routine hospital setting, provides clinically actionable cancer genotype information in a large fraction of patients with CNS tumors.
PMCID:11406943
PMID: 39289779
ISSN: 2051-5960
CID: 5720692

A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine

Latzer, Pauline; Zelba, Henning; Battke, Florian; Reinhardt, Annekathrin; Shao, Borong; Bartsch, Oliver; Rabsteyn, Armin; Harter, Johannes; Schulze, Martin; Okech, Thomas; Golf, Alexander; Kyzirakos-Feger, Christina; Kayser, Simone; Pieper, Natalia; Feldhahn, Magdalena; Wünsche, Julian; Seitz, Christian; Hadaschik, Dirk; Garbe, Claus; Hauser, Till-Karsten; la Fougère, Christian; Biskup, Dirk; Brooke, Dawn; Parker, David; Martens, Uwe M; Illerhaus, Gerald; Blumenthal, Deborah T; Merrell, Ryan; Lorenzo, Luisa Sánchez; Hidvégi, Máté; de Robles, Paula; Kebir, Sied; Li, William W; Li, Vincent W; Williams, Matthew; Miller, Alexandra M; Kesari, Santosh; Castro, Michael; Desjardins, Annick; Ashley, David M; Friedman, Henry S; Wen, Patrick Y; Neil, Elisabeth C; Iwamoto, Fabio M; Sipos, Bence; Geletneky, Karsten; Zender, Lars; Glas, Martin; Reardon, David A; Biskup, Saskia
Current treatment outcome of patients with glioblastoma (GBM) remains poor. Following standard therapy, recurrence is universal with limited survival. Tumors from 173 GBM patients are analysed for somatic mutations to generate a personalized peptide vaccine targeting tumor-specific neoantigens. All patients were treated within the scope of an individual healing attempt. Among all vaccinated patients, including 70 treated prior to progression (primary) and 103 treated after progression (recurrent), the median overall survival from first diagnosis is 31.9 months (95% CI: 25.0-36.5). Adverse events are infrequent and are predominantly grade 1 or 2. A vaccine-induced immune response to at least one of the vaccinated peptides is detected in blood samples of 87 of 97 (90%) monitored patients. Vaccine-specific T-cell responses are durable in most patients. Significantly prolonged survival is observed for patients with multiple vaccine-induced T-cell responses (53 months) compared to those with no/low induced responses (27 months; P = 0.03). Altogether, our results highlight that the application of personalized neoantigen-targeting peptide vaccine is feasible and represents a promising potential treatment option for GBM patients.
PMCID:11316744
PMID: 39127809
ISSN: 2041-1723
CID: 5697022

Systematic Review of Cerebrospinal Fluid Biomarker Discovery in Neuro-Oncology: A Roadmap to Standardization and Clinical Application

Mikolajewicz, Nicholas; Yee, Patricia P; Bhanja, Debarati; Trifoi, Mara; Miller, Alexandra M; Metellus, Philippe; Bagley, Stephen J; Balaj, Leonora; de Macedo Filho, Leonardo J M; Zacharia, Brad E; Aregawi, Dawit; Glantz, Michael; Weller, Michael; Ahluwalia, Manmeet S; Kislinger, Thomas; Mansouri, Alireza
Effective diagnosis, prognostication, and management of CNS malignancies traditionally involves invasive brain biopsies that pose significant risk to the patient. Sampling and molecular profiling of cerebrospinal fluid (CSF) is a safer, rapid, and noninvasive alternative that offers a snapshot of the intracranial milieu while overcoming the challenge of sampling error that plagues conventional brain biopsy. Although numerous biomarkers have been identified, translational challenges remain, and standardization of protocols is necessary. Here, we systematically reviewed 141 studies (Medline, SCOPUS, and Biosis databases; between January 2000 and September 29, 2022) that molecularly profiled CSF from adults with brain malignancies including glioma, brain metastasis, and primary and secondary CNS lymphomas. We provide an overview of promising CSF biomarkers, propose CSF reporting guidelines, and discuss the various considerations that go into biomarker discovery, including the influence of blood-brain barrier disruption, cell of origin, and site of CSF acquisition (eg, lumbar and ventricular). We also performed a meta-analysis of proteomic data sets, identifying biomarkers in CNS malignancies and establishing a resource for the research community.
PMID: 38608213
ISSN: 1527-7755
CID: 5770622

Real-World Use of Hypofractionated Radiotherapy for Primary CNS Tumors in the Elderly, and Implications on Medicare Spending

Tringale, Kathryn R; Lin, Andrew; Miller, Alexandra M; Khan, Atif; Chen, Linda; Zinovoy, Melissa; Yamada, Yoshiya; Yu, Yao; Pike, Luke R G; Imber, Brandon S
BACKGROUND:For elderly patients with high-grade gliomas, 3-week hypofractionated radiotherapy (HFRT) is noninferior to standard long-course radiotherapy (LCRT). We analyzed real-world utilization of HFRT with and without systemic therapy in Medicare beneficiaries treated with RT for primary central nervous system (CNS) tumors using Centers for Medicare & Medicaid Services data. METHODS:Radiation modality, year, age (65-74, 75-84, or ≥85 years), and site of care (freestanding vs hospital-affiliated) were evaluated. Utilization of HFRT (11-20 fractions) versus LCRT (21-30 or 31-40 fractions) and systemic therapy was evaluated by multivariable logistic regression. Medicare spending over the 90-day episode after RT planning initiation was analyzed using multivariable linear regression. RESULTS:From 2015 to 2019, a total of 10,702 RT courses (ie, episodes) were included (28% HFRT; 65% of patients aged 65-74 years). A considerable minority died within 90 days of RT planning initiation (n=1,251; 12%), and 765 (61%) of those received HFRT. HFRT utilization increased (24% in 2015 to 31% in 2019; odds ratio [OR], 1.2 per year; 95% CI, 1.1-1.2) and was associated with older age (≥85 vs 65-74 years; OR, 6.8; 95% CI, 5.5-8.4), death within 90 days of RT planning initiation (OR, 5.0; 95% CI, 4.4-5.8), hospital-affiliated sites (OR, 1.4; 95% CI, 1.3-1.6), conventional external-beam RT (vs intensity-modulated RT; OR, 2.7; 95% CI, 2.3-3.1), and no systemic therapy (OR, 1.2; 95% CI, 1.1-1.3; P<.001 for all). Increasing use of HFRT was concentrated in hospital-affiliated sites (P=.002 for interaction). Most patients (69%) received systemic therapy with no differences by site of care (P=.12). Systemic therapy utilization increased (67% in 2015 to 71% in 2019; OR, 1.1 per year; 95% CI, 1.0-1.1) and was less likely for older patients, patients who died within 90 days of RT planning initiation, those who received conventional external-beam RT, and those who received HFRT. HFRT significantly reduced spending compared with LCRT (adjusted β for LCRT = +$8,649; 95% CI, $8,544-$8,755), whereas spending modestly increased with systemic therapy (adjusted β for systemic therapy = +$270; 95% CI, $176-$365). CONCLUSIONS:Although most Medicare beneficiaries received LCRT for primary brain tumors, HFRT utilization increased in hospital-affiliated centers. Despite high-level evidence for elderly patients, discrepancy in HFRT implementation by site of care persists. Further investigation is needed to understand why patients with short survival may still receive LCRT, because this has major quality-of-life and Medicare spending implications.
PMID: 38688308
ISSN: 1540-1413
CID: 5770632

Leveraging archival cerebrospinal fluid samples for genetic insights from cell-free DNA [Editorial]

Miller, Alexandra M; Bale, Tejus A
PMID: 38427323
ISSN: 1934-6638
CID: 5770612

Clinical applications of cerebrospinal fluid liquid biopsies in central nervous system tumors

Diaz, Maria; Chudsky, Sofia; Pentsova, Elena; Miller, Alexandra M
For patients with central nervous system (CNS) malignancies, liquid biopsies of the cerebrospinal fluid (CSF) may offer an unparalleled source of information about the tumor, with much less risk than traditional biopsies. Two techniques have been adapted to CSF in clinical settings: circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA). CTCs have been employed mostly as a diagnostic tool for leptomeningeal metastases in epithelial tumors, although they may also have value in the prognostication and monitoring of this disease. The ctDNA technology has been studied in a variety of primary and metastatic brain and spinal cord tumors, where it can be used for diagnosis and molecular classification, with some work suggesting that it may also be useful for longitudinal tracking of tumor evolution or as a marker of residual disease. This review summarizes recent publications on the use of these two tests in CSF, focusing on their established and potential clinical applications.
PMCID:10825768
PMID: 38218027
ISSN: 1936-5233
CID: 5770592